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Abstract
Background: Experimental and epidemiological evidence suggests that homocysteine (tHcy) may be a causal risk
factor for atherosclerosis. B-vitamin supplements reduce tHcy and improve endothelial function in short term
trials, but the long-term effects of the treatment on vascular structure and function are unknown.
Methods:  We conducted a sub-study of VITATOPS, a randomised, double-blind, placebo-controlled
intervention trial designed to test the efficacy of long term B-vitamin supplementation (folic acid 2 mg, vitamin B6
25 mg and vitamin B12 0.5 mg) in the prevention of vascular events in patients with a history of stroke. We
measured carotid intima-medial thickness (CIMT) and flow-mediated dilation (FMD) at least two years after
randomisation in 162 VITATOPS participants. We also conducted a systematic review and meta-analysis of
studies designed to test the effect of B-vitamin treatment on CIMT and FMD.
Results: After a mean treatment period of 3.9 ± 0.9 years, the vitamin-treated group had a significantly lower
mean plasma homocysteine concentration than the placebo-treated group (7.9 μmol/L, 95% CI 7.5 to 8.4 versus
11.8 μmol/L, 95% CI 10.9 to 12.8, p < 0.001). Post-treatment CIMT (0.84 ± 0.17 mm vitamins versus 0.83 ± 0.18
mm placebo, p = 0.74) and FMD (median of 4.0%, IQR 0.9 to 7.2 vitamins versus 3.0%, IQR 0.6 to 6.6 placebo, p
= 0.48) did not differ significantly between groups. A meta-analysis of published randomised data, including those
from the current study, suggested that B-vitamin supplements should reduce CIMT (-0.10 mm, 95% CI -0.20 to -
0.01 mm) and increase FMD (1.4%, 95% CI 0.7 to 2.1%). However, the improvement in endothelial function
associated with homocysteine-lowering treatment was significant in short-term studies but not in longer trials.
Conclusion: Although short-term treatment with B-vitamins is associated with increased FMD, long-term
homocysteine-lowering did not significantly improve FMD or CIMT in people with a history of stroke.
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Background
An elevated plasma homocysteine concentration (tHcy) is
associated an increased risk of myocardial infarction and
stroke [1-4]. It remains unclear, however, whether tHcy is
a modifiable causal risk factor for vascular disease or sim-
ply a marker of risk burden. If homocysteine causes vascu-
lar damage, lowering tHcy ought to slow the progression
of atherosclerosis and prevent atherothrombotic events.
Studies that have reduced plasma homocysteine concen-
trations with B-vitamin supplements have produced con-
flicting results. Several short-term intervention studies
show that lowering tHcy improves the surrogate vascular
outcomes of carotid intima-media thickness (CIMT) and
flow-mediated dilation (FMD) [5-10]. By contrast, B-vita-
min treatment has not reduced vascular mortality or mor-
bidity, with the possible exception of ischemic stroke, in
the large randomised clinical trials published to date
[11,12].
The aim of this study was to determine whether long-term
homocysteine-lowering treatment with folic acid, vitamin
B6 and vitamin B12 would reduce CIMT and increase FMD
in subjects with a history of stroke. We also carried out a
systematic review and meta-analysis to obtain an estimate
of the effect of B-vitamin treatment on these vascular
measurements based on the totality of published ran-
domised evidence.
Methods
The study was conducted in accordance with the Declara-
tion of Helsinki. The Royal Perth Hospital Ethics Commit-
tee approved the study protocol and each subject gave
written informed consent prior to taking part.
Participants
Study subjects were recruited from participants in the Vita-
mins TO Prevent Stroke (VITATOPS) trial. VITATOPS is a
large, international, randomised, double-blind, placebo-
controlled clinical trial designed primarily to examine the
efficacy and safety of B-group vitamins in the prevention
of stroke, myocardial infarction or death from any vascu-
lar cause among patients with previous stroke or transient
ischemic attack (TIA). The inclusion and exclusion criteria
for the VITATOPS trial have been reported previously
[13]. VITATOPS has enrolled a total of 976 people in Aus-
tralia and almost 8000 people worldwide. The trial is
expected to report its findings in 2010.
Design
The current study was a cross-sectional single-centre sub-
study of the VITATOPS trial. All VITATOPS participants
enrolled in Perth, Australia between 1998 and 2003 were
eligible for inclusion (n = 532). Subjects who had died,
withdrawn from VITATOPS, were severely handicapped or
had moved away from Perth were excluded (n = 189).
Recruitment letters were sent to all subjects suitable for
inclusion (n = 343). Subjects who responded positively to
the letter were contacted by telephone and enrolled in this
study (n = 173). The ethics approval for the project stipu-
lated that we should not contact subjects who did not
respond to the invitation letter, so non-responders were
not followed up.
Intervention
Participants in the VITATOPS trial were randomly
assigned at baseline to a single daily tablet containing
folic acid 2 mg, vitamin B6 25 mg, and vitamin B12 500 μg
or a matching placebo. A central 24-hour telephone serv-
ice and an interactive website used random permuted
blocks stratified by hospital to allocate a treatment pack
number.
Objectives
We aimed to determine whether long-term (greater than
two years) homocysteine-lowering treatment with B-vita-
min supplements would reduce CIMT and increase FMD
compared with placebo in subjects with a history of stroke
or TIA.
Outcomes
CIMT and FMD were the outcome measures chosen for
this sub-study. The vascular outcomes were not measured
at baseline and were assessed at a single time point at least
two years after randomisation. All participants attended a
morning appointment after an overnight fast. They were
also asked to withhold their morning medications,
including the VITATOPS tablet, and to refrain from smok-
ing and drinking alcohol or caffeine-containing beverages
for at least six hours prior to the study appointment. Age,
gender, details of the primary event, medications, cardio-
vascular risk factors and smoking history were recorded
and blood pressure, height, weight, waist and hip girth
and FMD and CIMT were measured. A fasting blood sam-
ple was collected to assess tHcy, red blood cell folate,
serum B6 and B12, total cholesterol, high- and low-density
lipoprotein (HDL and LDL) cholesterol, triglycerides, cre-
atinine and glucose.
CIMT and FMD were measured using techniques
described previously [14,15]. Briefly, the subject lay
supine on a flat examination couch in a quiet laboratory
and B-mode ultrasound images were recorded using a 10
MHz multi-frequency linear array probe attached to a
high-resolution ultrasound (Acuson Aspen, Mountain
View, California). Digital images of the right and left com-
mon carotid arteries immediately proximal to the bifurca-
tion were obtained from posterior, lateral and anterior
angles. Mean CIMT was measured off-line using edge-
tracking software. The final CIMT values for each subject
were calculated as the mean of six measurements. A previ-BMC Cardiovascular Disorders 2008, 8:24 http://www.biomedcentral.com/1471-2261/8/24
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ous study by our group indicates that the intra-observer
coefficient of variation for CIMT measured using this
method is 2.4% [14].
FMD was measured in the left arm except in subjects with
a left hemiplegia (n = 18). B-mode images of the brachial
artery were obtained and recorded continuously for one
minute to assess baseline arterial diameter. A rapid infla-
tion/deflation pneumatic cuff placed around the forearm
was inflated to 250 mmHg for five minutes. Post cuff-
deflation images were recorded continuously for two min-
utes to capture peak arterial dilation. When fifteen min-
utes had elapsed, a second scan was recorded to re-
establish baseline diameter. 400 μg of sub-lingual glyeryl
trinitrite (GTN) was administered to the subject and
images were recorded for eight minutes. FMD and GTN-
mediated dilation were measured off-line using edge-
detection software designed to minimise observer biases.
A single observer blinded to treatment status performed
all measurements. The mean intra-observer CV's for FMD
and GTN-mediated dilation measured by this technique
are 6.7% and 3.9% respectively [15].
Sample Size
We aimed to recruit sufficient subjects from the Perth
VITATOPS cohort to provide 80% power (α = 0.05) to
detect differences of 0.1 mm in mean CIMT and 2% in
FMD between the vitamin and placebo groups. Post-hoc
calculations for a one-sided test showed that the study had
80% power (α = 0.05) to detect a reduction in mean CIMT
of 0.07 mm and an absolute increase in FMD of 1.6%.
Statistical analysis
As the FMD data had a non-normal distribution and mul-
tiple zero values, we used a two-sample rank sum test
(Mann-Whitney) to compare the median FMD in the
treatment and placebo groups. Two-sample t-tests were
used to compare all normally distributed variables and
results are reported as mean ± standard deviation. Varia-
bles with log-normal distributions were log-transformed
and results for these variables are reported as geometric
mean (95% confidence interval). Proportions were com-
pared using a normal approximation to the binomial.
Effect size was calculated as the standardised difference
between treatment group means (Cohen's d) using
Hedges' correction for bias. Minitab (Version 14.2, Min-
itab Inc, USA) and SPSS (Version 15.0, SPSS Inc, USA)
were used for statistical analyses. A single observer
blinded to treatment group conducted the statistical anal-
ysis.
Systematic review and meta-analysis
We conducted a systematic review and meta-analysis of
randomised controlled trials reporting the effect of homo-
cysteine-lowering treatment with B-vitamin supplements
on FMD and CIMT. Papers were identified in the Medline
(1950 to January 2008) and EMBASE (1988 to January
2008) databases and with a manual search of citations in
the relevant retrieved papers. The search strategy was
(carotid intima media or intima medial thickness or IMT)
AND (folate or folic acid or folic) for CIMT papers and (flow-
mediated dilation or  endothelial function or  FMD) AND
(folate or folic acid or folic) for the FMD papers. Figure 1
shows the paper selection process for both analyses. We
included all randomised, placebo-controlled, double-
blind studies and open-label trials where observers assess-
ing the outcomes were blinded to treatment allocation.
We excluded studies that reported FMD as an absolute
change in brachial artery diameter because accurate stand-
ard deviations could not be calculated for the percent
change. The number of subjects, the post-treatment mean
and the standard deviation in CIMT (mm) and FMD (%)
in the vitamin and placebo groups were entered into the
meta-analysis software (Review Manager (RevMan) soft-
ware, version 4.2.10, Copenhagen, The Cochrane Collab-
oration). Pooled estimates were calculated from weighted
mean differences using a random effects model. Sub-
group analyses by treatment period and subject type were
conducted for the FMD studies. We performed sensitivity
analyses by deleting studies one at a time, creating funnel
plots, and comparing the results of a fixed effect model
with those from a random effects model.
Results
Subject recruitment and participant flow
Subjects recruited for this sub-study initiated treatment
between November 1998 and December 2003. Follow-up
data was collected between August 2004 and July 2006
after a minimum of two years of continuous treatment.
Participant flow is shown in Figure 2. The proportion of
VITATOPS subjects excluded due to withdrawal, death,
disability or geographical inaccessibility was similar in the
treatment and placebo groups. Approximately half of the
subjects eligible for inclusion in this sub-study agreed to
participate and had follow-up data collected. A greater
proportion of the participants were male and almost half
as many participants as non-participants had had a haem-
orrhagic stroke. No other significant differences between
participants and non-participants were detected in the
clinical characteristics recorded at enrolment (Table 1).
Numbers analysed
173 subjects had follow-up data collected. We conducted
an on-treatment analysis and thus excluded data from
eleven subjects, seven from the placebo group and four
from the vitamin group. Eight subjects were taking open-
label supplements containing folic acid or B-vitamins,
two had stopped taking the VITATOPS tablets and one
had been taking the VITATOPS medication for less than
two years. Results from four additional subjects wereBMC Cardiovascular Disorders 2008, 8:24 http://www.biomedcentral.com/1471-2261/8/24
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Flow chart showing the meta-analysis paper selection process and exclusion reasons Figure 1
Flow chart showing the meta-analysis paper selection process and exclusion reasons. A CIMT paper-selection flow 
chart. B FMD paper-selection flow chart.
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Potential CIMT studies 
identified and screened   
(n = 32)  Excluded    23 
Observational study    17 
Other treatments tested  3 
Review   2 
Unrelated to topic    1 
CIMT studies retrieved for 
detailed evaluation   
(n = 9) 
Excluded      3 
Other treatments tested  2 
No suitable control group  1 
CIMT studies included 
(n = 6) 
  Potential FMD studies 
identified and screened   
(n=198) 
Excluded    138 
Review or comment     78 
Observational study    23 
Animal or cellular    13 
FMD not an outcome   11 
Unrelated to topic    7 
Other treatments tested  6 
FMD studies retrieved for 
detailed evaluation 
(n = 60)  Excluded      40 
No suitable control group  13 
Plethysmography   9 
FMD not reported as %  7 
Insufficient information  6 
Duplicate  data    2 
Other treatments tested  2 
Methionine loading    1  FMD studies included 
(n= 20) 
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excluded from the FMD analysis, two from the placebo
group (poor scan quality and cigarette smoking less than
six hours prior to the study session) and two from the vita-
min group (food intake and cigarette smoking less than
six hours prior to the study session).
Baseline and follow-up data
The demographic and clinical characteristics of each
group at baseline and follow-up are presented in Table 2.
There were no significant differences in these variables
between the groups at baseline or follow-up. The systolic
blood pressure appeared to be lower in the vitamin group
at follow-up, but the difference was not significant when
corrected for baseline values (p = 0.19). Blood results are
presented in Table 3. Mean tHcy was lower at baseline in
the subjects randomised to vitamins and had dropped by
a further 23% at follow-up. As expected, the vitamin
group had significantly higher red blood cell folate, serum
B6 and serum B12 levels at follow-up than the placebo
group.
Vascular outcomes and estimated effect size
The vascular outcome measurements are presented in
Table 4. The mean CIMT in the vitamin group was not sig-
nificantly different from the mean CIMT in the placebo
group at follow-up. The mean difference between groups
was 0.01 mm (95% CI -0.04 mm, 0.06 mm). The esti-
mated effect size was 0.06 (95% CI -0.25, 0.37). The
median FMD in the vitamin group was not significantly
different from the median FMD in the placebo group at
follow-up. The mean difference between the groups was
0.5% (95% CI -0.73%, 1.73%). The effect size was 0.12
(95% CI -0.19, 0.44). We did not find any significant dif-
ferences in the effect of B-vitamins on CIMT or FMD
among the etiological subtypes of stroke. Results from an
intention-to-treat analysis were not substantially different
from the on-treatment analysis reported here.
Systematic review and meta-analysis
We identified six randomised placebo-controlled studies
that measured the effect of B-vitamin treatment on CIMT.
The pooled estimate from these studies was a significant
reduction in CIMT of 0.13 mm (95%CI -0.25, -0.01 mm,
n = 606, p = 0.03, I2 = 84.1%) in vitamin-treated subjects
compared with placebo (Figure 3). The inclusion of our
data reduced the estimated effect to -0.10 mm and nar-
rowed the confidence interval to -0.20 to -0.01 mm (n =
768, p = 0.04, I2 = 84.9%). Using a fixed-effect versus a
random-effects model did not substantially alter the
pooled estimate. However, removing the Vianna (2007)
Table 1: Demographic and clinical characteristics of subjects eligible for inclusion
Participants (n = 173) Non-participants (n = 170) p-value
Age at event (years) 65 ± 11 64 ± 14 0.58
Sex (male) 126 (73) 96 (56) < 0.01
Stroke type
Ischemic 124 (72) 117 (69) 0.33
TIA 34 (20) 28 (16)
Haemorrhagic 13 (7) 22 (13)
Unknown 2 (1) 3 (2)
Medications
Antiplatelet agent 140 (81) 131 (77) 0.40
Warfarin 28 (16) 30 (18) 0.76
Statin 57 (33) 51 (30) 0.54
Antihypertensive agent 97 (56) 83 (49) 0.20
Risk factors
Hypertension* 120 (69) 105 (62) 0.14
Hypercholesterolemia† 61 (35) 50 (30) 0.31
Diabetes‡ 29 (17) 32 (19) 0.71
Current smoker 33 (19) 31 (18) 0.84
Clinical characteristics
Systolic BP (mmHg) 133 ± 18 134 ± 18 0.75
Diastolic BP (mmHg) 78 ± 10 78 ± 10 0.78
GFR (ml/min/1.73 m2)§ 87 ± 21 90 ± 27 0.35
Values are mean ± standard deviation or number (%)
P-values for continuous variables are from a two-sample t-test, from a normal approximation to the binomial for proportions and from a chi-square 
test for categories.
TIA indicates transient ischemic attack of eye or brain; BMI, body mass index; BP, blood pressure, GFR, glomerular filtration rate.
*History of previous or current hypertension
†Treated for hypercholesterolaemia
‡ Includes type I, type II and impaired fasting glycaemia
§Estimated using the Modification of Diet in Renal Disease Study equation [32]BMC Cardiovascular Disorders 2008, 8:24 http://www.biomedcentral.com/1471-2261/8/24
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Flow chart showing the recruitment process for this study Figure 2
Flow chart showing the recruitment process for this study.












Withdrawn     n = 47 
Deceased    n = 33 
Disabled/unwell  n = 12 
Moved away    n = 3 
Letter sent     n = 169 
No response     n = 49 
Declined    n = 26 
Screened      n = 5 
Did not attend   n = 3 
Attended follow-up   n = 86 
Taking B-vitamins  n = 5 
Stopped treatment  n = 1 
<2 years treatment  n = 1 
Placebo  n = 264 
Data analysed    n = 79 
Withdrawn     n = 44 
Deceased    n = 35 
Disabled/unwell  n = 11 
Moved away    n = 4 
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Did not attend   n = 3 
Attended follow-up   n = 87 
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Taking B-vitamins  n = 3 
Stopped treatment  n = 1 
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Vitamins     n = 268 
Data analysed    n = 83  Analysis 
Baseline measurements 
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data from the analysis reduced the pooled estimate to
non-significance (-0.06 mm, 95% CI -0.13, 0.02) [7]. A
funnel plot of effect size versus study precision was asym-
metrical with a relative dearth of moderately precise neg-
ative studies, suggesting the presence of a positive
publication bias (Figure 4A).
We identified twenty randomised controlled trials that
met our inclusion criteria for measuring the effect of B-
vitamins on FMD. The pooled estimate, including our
data, was an absolute increase in FMD of 1.4% (95%CI
0.7, 2.1%, n = 1280, p < 0.0001) in vitamin-treated sub-
jects compared with placebo (Figure 5). When studies
were divided by treatment period, the significant
improvement in FMD in short-term studies (less than
eight weeks treatment) was not apparent in longer-term
studies. When the studies were analysed according to sub-
ject type, treatment with B-vitamins improved FMD in
subjects with diabetes (3.5%, 95% CI 2.3, 4.7%, n = 170)
and in those with coronary artery disease (1.9%, 95%CI
0.4, 3.4%, n = 347), but had no significant effect on FMD
in healthy subjects with elevated tHcy (1.0%, 95%CI -0.2,
2.3%, n = 204), in subjects with renal impairment (0.2%,
95% CI -0.8, 1.3%, n = 161) or in subjects with risk factors
for cardiovascular disease such as a family history of vas-
cular disease, hypercholesterolemia or hypertension (-
0.1%, 95% CI -2.1, 1.9%, n = 197).
Removing individual studies did not substantially alter
the estimated effect, and nor were there any differences
between results obtained using the fixed-effect versus the
random-effects model. Including the seven studies that
reported FMD as an absolute change in brachial artery
diameter by using mean standardised differences did not
change the overall result or the results of the sub-group
analyses. A funnel plot of effect size against study preci-
sion appeared to be symmetrical (Figure 4B).
Discussion
We found that long-term homocysteine-lowering with
folic acid, vitamin B6 and vitamin B12 did not reduce CIMT
or increase FMD in individuals with a history of stroke.
Table 2: Subject characteristics at baseline and follow-up
Baseline Follow-up
Placebo (n = 79) Vitamins (n = 83) Placebo (n = 79) Vitamins (n = 83)
Age (years) 65 ± 11 64 ± 12 69 ± 11 68 ± 12
Sex (male) 56 (71) 61 (73) 56 (71) 61 (73)
Treatment period (years) - - 3.8 ± 0.9 4.0 ± 0.9
Stroke type
Ischemic 54 (69) 62 (75) - -
TIA 19 (24) 13 (16) - -
Haemorrhagic 4 (5) 8 (10) - -
Unknown 2 (3) 0 (0) - -
Medications
Antiplatelet agent 68 (86) 63 (76) 60 (76) 59 (71)
Warfarin 11 (14) 16 (19) 13 (17) 15 (18)
Statin 24 (32) 30 (36) 59 (75) 56 (68)
Antihypertensive agent 47 (60) 45 (54) 69 (87) 71 (86)
Risk factors
Hypertension* 57 (72) 63 (75) 69 (87) 71 (86)
Hypercholesterolemia† 25 (32) 29 (35) 59 (75) 56 (68)
Diabetes‡ 14 (18) 15 (18) 22 (28) 19 (23)
Current smoker 15 (19) 18 (22) 7 (9) 7 (8)
Fruit (pieces/day) - - 1.7 ± 1.3 1.6 ± 1.1
Vegetables (serves/day) - - 3.5 ± 1.1 3.5 ± 1.2
Clinical characteristics
BMI (kg/m2) - - 29.3 ± 4.9 29.1 ± 4.8
Waist circumference (cm) - - 103 ± 12 103 ± 13
Systolic BP (mmHg) 135 ± 15 132 ± 16 145 ± 19 140 ± 16
Diastolic BP (mmHg) 78 ± 9 78 ± 10 79 ± 11 78 ± 10
GFR (ml/min/1.73 m2)§ 84 ± 19 88 ± 21 79 ± 18 77 ± 24
Values are mean ± standard deviation or number (%)
TIA indicates transient ischemic attack of eye or brain; BMI, body mass index; BP, blood pressure, GFR, glomerular filtration rate.
*History of previous or current hypertension
†Treated for hypercholesterolaemia
‡ Includes type I, type II and impaired fasting glycaemia
§Estimated using the Modification of Diet in Renal Disease Study equation [50]BMC Cardiovascular Disorders 2008, 8:24 http://www.biomedcentral.com/1471-2261/8/24
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When we included our results with data from similar ran-
domised trials in a meta-analysis the estimated pooled
effect was a modest improvement in both CIMT and FMD.
The 95% confidence intervals for the effect of B-vitamin
supplementation on CIMT (-0.04 mm, 0.06 mm) and
FMD (-0.73%, 1.73%) in our study overlap with confi-
dence intervals from the meta-analyses of -0.25 mm to -
0.01 mm and 0.73% to 2.23% (current data excluded),
indicating that our results are consistent with pooled data
from similar randomised studies. In a recent systematic
review and meta-analysis, Lorenz et al. report that a differ-
ence of 0.1 mm in CIMT predicts a 10% to 15% reduction
in the risk of future MI and a 13% to 18% reduction in the
risk of future stroke [16]. To the best of our knowledge, a
similar calculation for the predicative value of an absolute
difference in FMD has not been reported. A recent study
by Yeboah et al. reports a 9% reduction (95% CI 1%,
17%) in the risk of a future cardiovascular event (cardio-
vascular disease death, myocardial infarction, stroke, con-
gestive heart failure, claudication, angioplasty or cardiac
bypass graft surgery) per unit SD in FMD, an absolute dif-
ference of approximately 1.2% [17]. Our meta-analyses
estimates for the effect of B-vitamin supplementation on
CIMT (-0.1 mm) and FMD (+1.4%) thus appear to be con-
sistent with a significant clinical benefit, a result that con-
flicts with randomised trial evidence that homocysteine-
lowering treatment does not significantly reduce mortality
or morbidity [12,18-22]. There are several possible expla-
nations for this discrepancy.
Table 3: Blood results at baseline and follow-up
Baseline Post-treatment Adjusted mean 
treatment difference
p-value
Placebo (n = 79) Vitamins (n = 83) Placebo (n = 79) Vitamins (n = 83)
tHcy μmol/L 11.7 (10.9, 12.6) 10.3 (9.6, 11.1) 11.8 (10.9, 12.8) 7.9 (7.5, 8.4) -3.7 ± 0.8 < 0.001
Serum B6 nmol/L 40 (36, 45) 34 (31, 38) 34 30, 38) 118 (116, 121) 79 ± 3 < 0.001
Serum B12 pmol/L 297 (266, 331) 317 (285, 351) 274 (248, 302) 638 (600, 680) 328 ± 25 < 0.001
RBC folate nmol/L 805 (732, 885) 884 (796, 982) 944 (839, 1061) 2534 (2401, 2673) 1475 ± 103 < 0.001
Cholesterol mmol/L 4.7 (4.5, 4.9) 4.8 (4.6, 5.0) 4.3 (4.2, 4.5) 4.4 (4.2, 4.6) -0.1 ± 0.2 0.63
Triglycerides mmol/L 1.4 (1.2, 1.5) 1.5 (1.3, 1.6) 1.3 (1.1, 1.4) 1.3 (1.1, 1.4) -0.1 ± 0.1 0.53
LDL* mmol/L - - 2.3 (2.1, 2.4) 2.3 (2.1, 2.4) - -
HDL mmol/L - - 1.3 (1.2, 1.4) 1.3 (1.2, 1.3) - -
Creatinine μmol/L 80 (76, 83) 79 (74, 84) 84 (81, 88) 88 (83, 90) 3.1 ± 3.0 0.30
Cystatin C mg/L 1.02 (0.97, 1.07) 1.05 (1.00, 1.11) 1.04 (0.99, 1.09) 1.08 (1.02, 1.15) 0.01 ± 0.03 0.69
GGT mmol/L - - 26 (22, 30) 30 (27, 34) - -
Glucose mmol/L 5.4 (5.3, 5.6) 5.5 (5.3, 5.7) 5.1 (4.9, 5.2) 5.2 (5.0, 5.4) 0.1 ± 0.2 0.59
HbA1c % - - 5.8 (5.6, 6.0) 5.9 (5.7, 6.1) - -
RBC indicates red blood cell; LDL, low density lipoprotein; HDL, high density lipoprotein; GGT, gamma glutamyl transpeptidase; HBA1c, glycated 
haemoglobin.
Baseline and follow-up values are presented as geometric mean (95% confidence interval)
Adjusted mean treatment differences are presented as mean ± standard error
P-values for the adjusted mean treatment differences are from a univariate general linear model.
* Calculated using the Friedewald equation
Table 4: Vascular outcome measurements
Placebo (n = 79) Vitamins (n = 83) p
Vascular Structure 
Carotid intima-medial thickness (mm) 0.83 ± 0.18 0.84 ± 0.17 0.74
Carotid lumen diameter (mm) 6.35 ± 0.72 6.49 ± 0.94 0.31
Brachial artery diameter (mm) 3.66 ± 0.67 3.84 ± 0.82 0.12
Vascular Function 
Flow-mediated dilation (%) 3.0 (0.6 – 6.6) 4.0 (0.9 – 7.2) 0.48
GTN-mediated dilation (%) 20.2 ± 7.4 20.2 ± 8.1 0.98
GTN indicates glyeryl trinitrate.
Values are mean ± standard deviation or median (inter-quartile range)
P-values are from a two-sample t-test or a two-sample rank test (Mann-Whitney)BMC Cardiovascular Disorders 2008, 8:24 http://www.biomedcentral.com/1471-2261/8/24
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One explanation is that the results of the CIMT meta-anal-
ysis are unreliable. Only a small number of studies have
measured the effect of B-vitamin treatment on CIMT (n =
768 subjects, including the current study), the results
show considerable heterogeneity (I2 = 85%), are strongly
influenced by a single study and are likely to have been
Change in CIMT associated with B-vitamin treatment in all randomised trials published to date Figure 3
Change in CIMT associated with B-vitamin treatment in all randomised trials published to date. Squares indicate 
the mean difference in CIMT between the vitamin-treated and placebo-treated groups: the size of the square is proportional to 
the number of subjects in the study and the horizontal line indicates the 95% confidence interval. Diamonds represent the 95% 
confidence intervals for the sub-total and total differences. Studies are ordered by effect size. WMD, weighted mean differ-
ence; CI, confidence interval; RF indicates subjects with renal failure as defined by authors; RTR, renal transplant recipients; 
CAD, coronary artery disease [5-7,28,33,34]
  
  
0.25]    
0.13]    
0.46, 0.22]     
0.12, 0.06]     
0.09, 0.05]     
0.15, 0.13]     
0.04, 0.06]     
     
Total (95% CI)        
 3  85                         383 100.00          -0.10 [-0.20, -0.01]
Test for heterogeneity: Chi² = 39.75, df = 6 (P < 0.00001), I² = 84.9%   
Test for overall effect: Z = 2.10 (P = 0.0   4)   
 0.5   1 
Favours placebo    
 0 -0.5 -1
Test for overall effect: Z = 0.36 (P = 0.7   2)   
 17.97      
    0.01 [ -     83      0.84(0.17)          79      0.83(0.18)     
Current Study    
Potter 2008 (Stroke)    
 12.91        -0.40 [-0.55, -
 15.97        -0.23 [-0.33, -
  5.68        -0.12 [-
 16.46        -0.03 [-
 17.52        -0.02 [-
 13.50        -0.01 [-
  
82.03        
-0.13 [-0.25, -0.01]
Previous studies    
Vianna 2007 (RF) [7]             60      1.69(0.35)          53      2.09(0.46)     
Marcu  cci 2003 (RTR) [5]          25      0.64(0.17)          28      0.87(0.19)     
Till 2005 (IMT>1mm) [6]          26      1.42(0.48)          24      1.54(0.71)     
Fernandez 2006   (CAD) [33]        61      0.69(0.20)          63      0.72(0.29)     
Zoungas 2006 (RF) [28]           120      1.04(0.23)         126      1.06(0.29)     
Austen 2006 (RT ) [34 R]               10      0.49(0.20)          10      0.50(0.11)     
Subtotal (95% CI)        
 302                         304
Test for heterogeneity: Chi² = 31.43, df = 5 (P < 0.00001), I² = 84.
Test for overall effect: Z = 2.16 (P = 0.0   3)   
1%       
Study   
[95% CI]  %    
  Weight   
  Mean (SD) n Mean (SD)    
     Vitamins 
n    
Difference in C MT  I   Weighted mean difference    Placebo      
 Favours vitamins
Funnel plots for CIMT and FMD meta-analyses Figure 4
Funnel plots for CIMT and FMD meta-analyses. A Standard error (mm) plotted against weighted mean difference (mm) 
for all CIMT studies included in meta-analysis. B. Standard error (%) plotted against weighted mean difference (%) for all FMD 
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influenced by publication biases. A large study (n = 819)
that has not yet published detailed data has recently
reported finding no difference between placebo and treat-
ment groups in mean CIMT after three years of treatment
with folic acid [23]. Adding this study to the CIMT meta-
analysis would double the subject numbers and signifi-
cantly reduce the estimated effect of homocysteine-lower-
ing treatment.
By contrast with the CIMT data, the FMD meta-analysis
results appear to be relatively robust with no clear evi-
dence of a publication bias. A similar meta-analysis has
also recently reported a positive effect of homocysteine-
lowering treatment on FMD (1.08%, 95%CI 0.57, 1.59%,
n = 732) [24]. A possible explanation for the discrepancy
between the apparent improvement in FMD in the meta-
analyses and the lack of improvement in clinical trial
Change in FMD associated with B-vitamin treatment in previous randomised controlled trials Figure 5
Change in FMD associated with B-vitamin treatment in previous randomised controlled trials. Squares indicate 
the mean difference in FMD between the vitamin and placebo groups: the size of the square is proportional to the number of 
subjects in the study and the horizontal line indicates the 95% confidence interval. Diamonds represent the 95% confidence 
intervals for the sub-total and total differences. Studies are ordered by effect size. WMD indicates weighted mean difference; 
CI, confidence interval; HC indicates subjects with hypercholesterolaemia as defined by study authors; Type II, type II diabetes 
mellitus; CAD, coronary artery disease; PAD, peripheral artery disease; RF, renal failure; HHcy, hyperhomocysteinemia; OB, 
obese; AMI, acute myocardial infarction; N, normal healthy subjects; Type I, type 1 diabetes mellitus; HT, hypertension; FHx, 
family history of cardiovascular disease; RTR, renal transplant recipients [8-10,34-50].
  
Study   Vitamins   Placebo  Difference in FMD  Weight  Weighted mean difference 
n  Mean (SD)  n Mean (SD)  95% CI  %   95% CI
Four weeks or less 
Lekakis 2004 (HC) [35]         17      7.10(3.10)          17      5.60(2.20)        4.45      1.50 [-0.31, 3.31]   
Title 2006 (Type II) [10]      19      5.80(4.80)          19      3.20(2.70)        3.55      2.60 [0.12, 5.08]    
Dinckal 2003 (CAD) [36]        15      9.40(2.30)          11      3.80(1.20)        5.07      5.60 [4.24, 6.96]    
    51                          47  13.07       3.31 [0.52, 6.10]
Test for heterogeneity: Chi² = 13.81, df = 2 (P = 0.001), I² = 85.5% 
Test for overall effect: Z = 2.33 (P = 0.02) 
Five to eight weeks 
Sydow 2003 (PAD) [37]           8      8.30(2.55)           8      8.90(1.98)        3.86     -0.60 [-2.84, 1.64]   
Bennett  2002 (RF) [38]       25      8.47(3.01)          25      8.80(4.01)        4.22     -0.33 [-2.30, 1.64]   
Olthof 2006 (HHcy) [39]       39      2.80(1.90)          39      2.80(1.80)       5.75      0.00 [-0.82, 0.82]   
Hirsh 2002b (HHcy) [40]        9      8.77(5.64)          11      8.07(7.95)        1.16      0.70 [-5.27, 6.67]   
Pena 2007 (OB) [41]           27      6.56(4.79)          26      5.79(4.27)        3.60      0.77 [-1.67, 3.21]   
Woodman 2004b (HHcy) [42]      13      8.70(4.70)          13      7.90(4.30)        2.52      0.80 [-2.66, 4.26]   
Woodman 2004a (HHcy) [42]      13      6.30(3.60)          13      5.30(2.50)        3.67      1.00 [-1.38, 3.38]   
Moens 2007a  (AMI) [43]        20      6.44(2.50)          20      5.42(2.64)        4.75      1.02 [-0.57, 2.61]   
Hirsch 2002a [40]              9      8.47(7.42)          11      7.34(2.55)        1.49      1.13 [-3.95, 6.21]   
Moens 2007b (AMI) [43]         20      6.49(2.50)          20      4.46(1.70)        5.12      2.03 [0.71, 3.35]    
Chambers 2000 (CAD) [9]       59      4.00(3.70)          30      1.90(2.60)        5.12      2.10 [0.77, 3.43]    
Woo 1999  (HHcy) [8]          17      8.20(1.60)          17      6.00(1.30)        5.57      2.20 [1.22, 3.18]    
Pena 2004b (Type I) [44]       15      5.50(3.80)          15      3.10(3.80)        3.26      2.40 [-0.32, 5.12]   
Pena 2004a (Type I) [44]       21      5.70(3.00)          21      2.40(3.10)        4.39      3.30 [1.45, 5.15]    
Makenzie2006(Type I) [45]      30     10.48(4.39)          30      5.44(3.37)        4.20      5.04 [3.06, 7.02]    
   325                         299  58.69      1.52 [0.72, 2.33]
Test for heterogeneity: Chi² = 40.03, df = 14 (P = 0.0003), I² = 65.0% 
Test for overall effect: Z = 3.71 (P = 0.0002) 
Nine to twelve weeks 
Carlsson 2004 (HT) [46]       20      2.40(4.90)          20      3.00(4.20)        3.14     -0.60 [-3.43, 2.23]   
Thambyrajah2001(CAD) [47]      43      4.50(3.08)          43      4.10(3.08)        5.16      0.40 [-0.90, 1.70]   
Thambyrajah2000 (RF) [48]      47      4.30(2.90)          44      3.90(3.45)        5.14      0.40 [-0.91, 1.71]   
   110                         107  13.44      0.30 [-0.58, 1.18]
Test for heterogeneity: Chi² = 0.43, df = 2 (P = 0.81), I² = 0% 
Test for overall effect: Z = 0.68 (P = 0.50) 
More than twelve weeks 
van Dijk 2001 (FHx) [49]       56      6.40(6.80)          57      8.00(6.20)        3.65     -1.60 [-4.00, 0.80]   
Potter 2007 (Stroke)       81      4.56(4.13)          79      4.06(3.83)        5.25      0.50 [-0.73, 1.73]   
Austen 2006 (RTR) [34]         10      7.00(4.90)          10      6.10(5.00)        1.88      0.90 [-3.44, 5.24]   
Title 2000 (CAD) [50]        25      5.20(3.90)          25      2.90(3.70)        4.03      2.30 [0.19, 4.41]    
   172                         171  14.80      0.53 [-0.99, 2.06]
Test for heterogeneity: Chi² = 5.76, df = 3 (P = 0.12), I² = 47.9% 
Test for overall effect: Z = 0.69 (P = 0.49) 
   658                         624 100.00      1.43 [0.72, 2.14]
Test for heterogeneity: Chi² = 92.64, df = 24 (P < 0.00001), I² = 74.1% 
Test for overall effect: Z = 3.95 (P < 0.0001) 
 -10  -5  0  5   10 
 Favours placebo   Favours vitamins BMC Cardiovascular Disorders 2008, 8:24 http://www.biomedcentral.com/1471-2261/8/24
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event rates is that the laboratory studies and the interven-
tion trials have been conducted in different subject
groups. Most clinical trials have recruited subjects with
existing vascular disease, either coronary artery [19-21,25-
27] or cerebrovascular disease [18], or with strong vascu-
lar risk factors such as diabetes [19] or renal impairment
[22,28,29]. While the effect of homocysteine-lowering on
FMD has also been assessed most frequently in subjects
with existing disease or vascular risk factors, many studies
have been conducted in healthy individuals.
It is possible that homocysteine-lowering treatment may
prove more effective in individuals without established
vascular disease, as a recent meta-analysis of clinical trial
data suggests that the incidence of new ischemic stroke is
significantly reduced by B-vitamin supplementation
whilst recurrent stroke is not [11]. However, our sub-
group analysis indicates that B-vitamin treatment
improves FMD in people with diabetes and coronary dis-
ease but not in healthy subjects. The discrepancy between
the FMD data and the clinical trial results is thus not
explained by the laboratory studies having been under-
taken in healthy individuals and the clinical trials in sub-
jects with established disease.
Our sub-group analysis also indicates that the significant
improvements in FMD associated with short-term folic
acid treatment are not sustained in longer-term studies
(Figure 5). Whether this observation reflects a true biolog-
ical effect, is due to publication biases, or to systematic
differences between short and long term trials with respect
to the characteristics of participants or dose of folic acid
dose is not clear. However, it raises the interesting ques-
tion of whether long-term exposure to B-vitamins might
have adverse effects on the vasculature that counteract any
short-term improvement in endothelial function. The
Heart Outcomes Prevention Evaluation (HOPE) 2 study
found that vitamin-treated subjects were more likely to be
admitted to hospital with unstable angina than those on
placebo (RR 1.24, 95% CI 1.04, 1.49) [19]. This finding
might be attributed to chance were it not for evidence that
B-vitamin therapy increases the risk of in-stent stenosis
and the need for revascularisation following angioplasty
[20,21]. The Norwegian Vitamin Trial (NORVIT) in 3749
men and women with a recent myocardial infarction also
found a small increase in the risk of the composite end-
point (recurrent myocardial infarction, stroke or sudden
death attributed to coronary artery disease) in the vitamin
group (RR 1.22, 95% CI 1.00, 1.50, p = 0.05) [27]. Excess
folic acid, through its growth-promoting effects, could
conceivably accelerate intimal hyperplasia and smooth
muscle cell proliferation in existing vascular lesions.
A more controversial explanation for the discrepancy
between the improvements in FMD and CIMT in our
meta-analysis and the negative results from the clinical tri-
als is that FMD and CIMT are not particularly reliable or
sensitive indicators of cardiovascular risk. Although FMD
and CIMT are widely and enthusiastically accepted as sur-
rogates for vascular events, the evidence linking these
measurements with hard clinical endpoints is relatively
weak and the small changes in FMD and CIMT associated
with B-vitamin treatment in our meta-analyses may actu-
ally have limited independent prognostic significance
[30,31].
Limitations
Our study has several strengths, namely its large size, long
duration and randomised, placebo-controlled, double-
blind design. Ours is the first study to investigate the
effects of B-vitamin supplementation on FMD and CIMT
in people with a history of stroke and TIA. By conducting
a systematic review and meta-analysis, we were able to
estimate the effect of B-vitamin treatment on FMD and
CIMT based on the totality of available randomised evi-
dence. This additional analysis puts our results in proper
context and allows for the addition of more randomised
data as they are published.
Our study also has limitations. We did not measure the
FMD or CIMT prior to randomisation and were thus una-
ble to adjust the post-treatment change in these measure-
ments for baseline values. The randomisation process
should have ensured that both groups had similar CIMT
and FMD at baseline, making it statistically valid to esti-
mate the effect of treatment by testing only the follow-up
measurements. By chance, however, the group ran-
domised to B-vitamins had a lower mean tHcy at baseline
than the group randomised to placebo. Although the two
groups were similar in all other clinical characteristics, we
cannot be sure that the mean CIMT and FMD were actu-
ally the same in both groups prior to treatment. However,
as tHcy is positively associated with CIMT and negatively
with FMD, any baseline differences in these measure-
ments between the groups should have increased rather
than reduced the probability of finding improved FMD
and CIMT in the vitamin group at follow-up.
A further limitation of the study is that, due to ethical con-
straints, we did not contact subjects who failed to respond
to the invitation letter. We collected usable data from only
30% of the subjects originally randomised, approximately
half of the subjects identified retrospectively as eligible for
inclusion. Apart from a higher proportion of males and
fewer haemorrhagic strokes, participants did not differ sig-
nificantly from the eligible non-participants in demo-
graphic or clinical characteristics and thus appeared to be
broadly representative of the larger cohort (Table 2). It is
likely however, that the participants in this study com-
prise an intelligent, motivated and compliant sub-groupBMC Cardiovascular Disorders 2008, 8:24 http://www.biomedcentral.com/1471-2261/8/24
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of VITATOPS subjects. Most participants had well-control-
led blood pressure and cholesterol levels, were on optimal
medical treatment and had healthy life-styles, factors that
may have reduced our ability to detect any additional vas-
cular benefits from the homocysteine-lowering treatment.
Selecting subjects who had survived for at least two years
after randomisation without severe disability may also
have influenced our results. If subjects with a low FMD or
high CIMT randomised to the vitamin group had
improved disability-free survival compared with similar
subjects randomised to placebo, they may have been over-
represented in the vitamin-group at follow-up, reducing
our chances of finding a between-group difference in the
vascular outcomes. However, we found no difference in
the number of subjects in each group excluded from the
current study due to death or disability, making it unlikely
that this potential source of bias substantially altered our
results.
Generalisability
It is not clear that our negative result can be extrapolated
to people with a history of stroke in the general popula-
tion. The majority of our subjects were on optimal medi-
cal treatment, which may have made it difficult to detect
any additional benefit from lowering tHcy. In addition,
the subjects were a self-selected group of trial participants
and were thus a highly motivated and compliant group of
individuals unlikely to be representative of the commu-
nity at large.
Conclusion
Our results indicate that long-term homocysteine-lower-
ing treatment with B-vitamins does not significantly
reduce CIMT or increase FMD in people with a history of
stroke. In addition, the modest increase in FMD associ-
ated with short-term B-vitamin treatment does not appear
to be translated into improved vascular structure or sus-
tained in the longer term.
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